A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Refractory or Relapsed Mantle Cell Lymphoma (MCL)

Trial Profile

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Refractory or Relapsed Mantle Cell Lymphoma (MCL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Zanubrutinib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors BeiGene
  • Most Recent Events

    • 13 Nov 2017 According to BeiGene media release, enrollment was completed in September 2017.
    • 13 Nov 2017 Status changed from recruiting to active, no longer recruiting, as reported in a BeiGene media release
    • 16 Jun 2017 According to a BeiGene media release, this trial is intended to support approval of BGB-3111 in China.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top